Cargando…
Prehospital tranexamic acid: what is the current evidence?
Many trauma systems are examining whether to implement prehospital tranexamic acid (TXA) protocols since hemorrhage remains the leading cause of potentially preventable early trauma mortality, and early in-hospital administration of TXA within 3 hours of injury is associated with reduced mortality....
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5877891/ https://www.ncbi.nlm.nih.gov/pubmed/29766078 http://dx.doi.org/10.1136/tsaco-2016-000056 |
_version_ | 1783310784706641920 |
---|---|
author | Napolitano, Lena M |
author_facet | Napolitano, Lena M |
author_sort | Napolitano, Lena M |
collection | PubMed |
description | Many trauma systems are examining whether to implement prehospital tranexamic acid (TXA) protocols since hemorrhage remains the leading cause of potentially preventable early trauma mortality, and early in-hospital administration of TXA within 3 hours of injury is associated with reduced mortality. But robust evidence regarding the efficacy of prehospital administration of the antifibrinolytic drug TXA on trauma outcomes is lacking. This review examines the current evidence available regarding prehospital TXA efficacy in both military and civilian trauma, and updates available evidence regarding in-hospital TXA efficacy in trauma. |
format | Online Article Text |
id | pubmed-5877891 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-58778912018-05-14 Prehospital tranexamic acid: what is the current evidence? Napolitano, Lena M Trauma Surg Acute Care Open Review Many trauma systems are examining whether to implement prehospital tranexamic acid (TXA) protocols since hemorrhage remains the leading cause of potentially preventable early trauma mortality, and early in-hospital administration of TXA within 3 hours of injury is associated with reduced mortality. But robust evidence regarding the efficacy of prehospital administration of the antifibrinolytic drug TXA on trauma outcomes is lacking. This review examines the current evidence available regarding prehospital TXA efficacy in both military and civilian trauma, and updates available evidence regarding in-hospital TXA efficacy in trauma. BMJ Publishing Group 2017-01-13 /pmc/articles/PMC5877891/ /pubmed/29766078 http://dx.doi.org/10.1136/tsaco-2016-000056 Text en Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/ This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
spellingShingle | Review Napolitano, Lena M Prehospital tranexamic acid: what is the current evidence? |
title | Prehospital tranexamic acid: what is the current evidence? |
title_full | Prehospital tranexamic acid: what is the current evidence? |
title_fullStr | Prehospital tranexamic acid: what is the current evidence? |
title_full_unstemmed | Prehospital tranexamic acid: what is the current evidence? |
title_short | Prehospital tranexamic acid: what is the current evidence? |
title_sort | prehospital tranexamic acid: what is the current evidence? |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5877891/ https://www.ncbi.nlm.nih.gov/pubmed/29766078 http://dx.doi.org/10.1136/tsaco-2016-000056 |
work_keys_str_mv | AT napolitanolenam prehospitaltranexamicacidwhatisthecurrentevidence |